103 related articles for article (PubMed ID: 28140088)
1. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial.
Hainsworth JD
Semin Oncol; 2002 Feb; 29(1S2):25-29. PubMed ID: 28140088
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
Hainsworth JD
Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
Hainsworth JD; Litchy S; Burris HA; Scullin DC; Corso SW; Yardley DA; Morrissey L; Greco FA
J Clin Oncol; 2002 Oct; 20(20):4261-7. PubMed ID: 12377971
[TBL] [Abstract][Full Text] [Related]
4. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
5. Rituximab as first-line systemic therapy for patients with low-grade lymphoma.
Hainsworth JD
Semin Oncol; 2000 Dec; 27(6 Suppl 12):25-9. PubMed ID: 11225997
[TBL] [Abstract][Full Text] [Related]
6. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
7. Prolonging remission with rituximab maintenance therapy.
Hainsworth JD
Semin Oncol; 2004 Feb; 31 Suppl 2():17-21. PubMed ID: 28140104
[TBL] [Abstract][Full Text] [Related]
8. Prolonging remission with rituximab maintenance therapy.
Hainsworth JD
Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1S2):56-69. PubMed ID: 28140093
[TBL] [Abstract][Full Text] [Related]
10. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: Ongoing and future clinical development.
Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
Semin Oncol; 2002 Feb; 29(1S2):105-112. PubMed ID: 28140083
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
13. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1S2):70-74. PubMed ID: 28140094
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
15. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
16. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
18. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
[TBL] [Abstract][Full Text] [Related]
19. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Leonard JP; Link BK
Semin Oncol; 2002 Feb; 29(1S2):81-86. PubMed ID: 28140096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
